These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38570184)

  • 1. Model-based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese patients with tuberculosis.
    Li JM; Zhang RY; Yang GY; Cai QS; Lang YZ; Zhong FM; Huang JP; Chen YY; Qin Y; Fang LK; Ye B; Lin LH; Lin HH; Cai XJ; Xu K
    Br J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38570184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations.
    Wang CY; Jiao Z; Ding JJ; Yu EQ; Zhu GX
    Epilepsy Behav; 2020 Oct; 111():107265. PubMed ID: 32640410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations.
    Yu EQ; Jiao Z; Wang CY; Ding JJ; Zhang XH
    Epilepsy Behav; 2019 Jul; 96():132-140. PubMed ID: 31132614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.
    Wilkins JJ; Langdon G; McIlleron H; Pillai G; Smith PJ; Simonsson US
    Br J Clin Pharmacol; 2011 Jul; 72(1):51-62. PubMed ID: 21320152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
    Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
    J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing.
    Liu XQ; Yin YW; Wang CY; Li ZR; Zhu X; Jiao Z
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1153-1163. PubMed ID: 34058934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Handling Delayed or Missed Dose of Antiseizure Medications: A Model-Informed Individual Remedial Dosing.
    Li ZR; Wang CY; Lin WW; Chen YT; Liu XQ; Jiao Z
    Neurology; 2023 Feb; 100(9):e921-e931. PubMed ID: 36450606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository.
    Ju G; Liu X; Yang W; Xu N; Chen L; Zhang C; He Q; Zhu X; Ouyang D
    Drug Des Devel Ther; 2024; 18():801-818. PubMed ID: 38500691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.
    Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6791-9. PubMed ID: 26282412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remedial Dosing Recommendations for Sirolimus Delayed or Missed Dosages Caused by Poor Medication Compliance in Pediatric Tuberous Sclerosis Complex Patients.
    Yang Y; Jiang L; Zhu HR; Sun WX; Mao JY; Miao JW; Wang YC; He SM; Wang DD; Chen X
    Curr Pharm Des; 2024; 30(11):877-886. PubMed ID: 38454763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study.
    Gao Y; Davies Forsman L; Ren W; Zheng X; Bao Z; Hu Y; Bruchfeld J; Alffenaar JW
    Br J Clin Pharmacol; 2021 Mar; 87(3):1347-1358. PubMed ID: 33464624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.
    Chen B; Shi HQ; Feng MR; Wang XH; Cao XM; Cai WM
    Front Pharmacol; 2022; 13():932686. PubMed ID: 35928262
    [No Abstract]   [Full Text] [Related]  

  • 15. Parametric population pharmacokinetics of isoniazid: a systematic review.
    Li J; Cai X; Chen Y; Wang C; Jiao Z
    Expert Rev Clin Pharmacol; 2023 May; 16(5):467-489. PubMed ID: 36971782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
    Béranger A; Bekker A; Solans BP; Cotton MF; Mirochnick M; Violari A; Wang J; Cababasay M; Wiesner L; Browning R; Moye J; Capparelli EV; Savic RM
    Clin Infect Dis; 2022 Sep; 75(6):1037-1045. PubMed ID: 35134861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing.
    Liu XQ; Li ZR; Wang CY; Jiao Z
    Blood Adv; 2024 Sep; ():. PubMed ID: 39293087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia.
    Fredj NB; Romdhane HB; Woillard JB; Chickaid M; Fadhel NB; Chadly Z; Chaabane A; Boughattas N; Aouam K
    Int J Infect Dis; 2021 Mar; 104():562-567. PubMed ID: 33476758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Nonadherence on Levetiracetam Pharmacokinetics and Remedial Dose Recommendations Using Monte Carlo Simulations.
    Methaneethorn J
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):667-676. PubMed ID: 35761145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.